Home » Stocks » Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. (SYRS)

Stock Price: $6.77 USD -0.76 (-10.09%)
Updated Oct 26, 2020 12:49 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 309.81M
Revenue (ttm) 6.63M
Net Income (ttm) -73.94M
Shares Out 45.76M
EPS (ttm) -1.69
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $6.77
Previous Close $7.53
Change ($) -0.76
Change (%) -10.09%
Day's Open 7.50
Day's Range 6.67 - 7.66
Day's Volume 193,510
52-Week Range 4.26 - 14.69

More Stats

Market Cap 309.81M
Enterprise Value 248.20M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 45.76M
Float 39.63M
EPS (basic) -1.70
EPS (diluted) -1.69
FCF / Share -1.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.85M
Short Ratio 10.77
Short % of Float 12.24%
Beta 1.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 46.71
PB Ratio 5.52
Revenue 6.63M
Operating Income -74.64M
Net Income -73.94M
Free Cash Flow -47.41M
Net Cash 61.61M
Net Cash / Share 1.35
Gross Margin 29.89%
Operating Margin -1,125.27%
Profit Margin -1,114.80%
FCF Margin -714.82%
ROA -31.14%
ROE -84.84%
ROIC -83.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$15.29*
(125.85% upside)
Low
10.0
Current: $6.77
High
20.0
Target: 15.29
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue1.982.051.100.320.32-
Revenue Growth-3.32%86.19%247.32%0%--
Gross Profit1.982.051.100.320.32-
Operating Income-77.74-64.30-54.69-47.96-29.82-13.44
Net Income-75.44-62.28-54.01-47.74-29.82-13.43
Shares Outstanding40.2232.6625.4112.701.981.53
Earnings Per Share-1.88-1.91-2.13-4.05-17.55-10.26
Operating Cash Flow-60.25-40.32-44.73-40.54-23.03-11.97
Capital Expenditures-12.53-1.38-0.82-2.32-1.18-0.20
Free Cash Flow-72.78-41.69-45.55-42.86-24.21-12.17
Cash & Equivalents91.7110072.2484.0836.3960.46
Total Debt25.920.030.050.220.34-
Net Cash / Debt65.7910072.1983.8636.0560.46
Assets15010778.4991.3243.6361.49
Liabilities70.7928.1813.1610.7291.6083.27
Book Value79.1878.5965.3280.60-47.96-21.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Syros Pharmaceuticals, Inc.
Country United States
Employees 83
CEO Nancy A. Simonian

Stock Information

Ticker Symbol SYRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SYRS
IPO Date June 30, 2016

Description

Syros Pharmaceuticals, a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and myelodysplastic syndrome; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.